Supplemental Data for Metabolic profiling of the novel HIF 2 α inhibitor PT 2385 in vivo and in vitro in Drug Metabolism and Disposition

Cen Xie,Xiaoxia Gao,Dongxue Sun,Youbo Zhang,Kristopher W. Krausz,Xuemei Qin,Frank J. Gonzalez

2018-01-01

Abstract:250 Introduction: 564 Discussion: 1046

What problem does this paper attempt to address?

Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro.

Cen Xie,Xiaoxia Gao,Dongxue Sun,Youbo Zhang,Kristopher W Krausz,Xuemei Qin,Frank J Gonzalez

DOI: https://doi.org/10.1124/dmd.117.079723

2018-01-01

Abstract:PT2385 is a first-in-class, selective small-molecule inhibitor of hypoxia-inducible factor-2α (HIF-2α) developed for the treatment of advanced clear cell renal cell carcinoma. Preclinical results demonstrated that PT2385 has potent antitumor efficacy in mouse xenograft models of kidney cancer. It also has activity toward metabolic disease in a mouse model. However, no metabolism data are currently publically available. It is of great importance to characterize the metabolism of PT2385 and identify its effect on systemic homeostasis in mice. High-resolution mass spectrometry-based metabolomics was performed to profile the biotransformation of PT2385 and PT2385-induced changes in endogenous metabolites. Liver microsomes and recombinant drug-metabolizing enzymes were used to determine the mechanism of PT2385 metabolism. Real-time polymerase chain reaction analysis was employed to investigate the reason for the PT2385-induced bile acid dysregulation. A total of 12 metabolites of PT2385 was characterized, generated from hydroxylation (M1, M2), dihydroxylation and desaturation (M3, M4), oxidative-defluorination (M7), glucuronidation (M8), N-acetylcysteine conjugation (M9), and secondary methylation (M5, M6) and glucuronidation (M10, M11, and M12). CYP2C19 was the major contributor to the formation of M1, M2, and M7, UGT2B17 to M8, and UGT1A1/3 to M10-M12. The bile acid metabolites taurocholic acid and tauro-β-muricholic acid were elevated in serum and liver of mice after PT2385 treatment. Gene expression analysis further revealed that intestinal HIF-2α inhibition by PT2385 treatment upregulated the hepatic expression of CYP7A1, the rate-limiting enzyme in bile acid synthesis. This study provides metabolic data and an important reference basis for the safety evaluation and rational clinical application of PT2385.
Supplementary Data File 3 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421120.v1

2023-01-01

Abstract:Pathway stability in PDXs across passages for Hallmark pathway set.
Supplementary Data File 4 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421117.v1

2023-01-01

Abstract:Pathway stability in PDXs across passages for Reactome pathway sets.
Supplementary Data File 5 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421114.v1

2023-01-01

Abstract:Analysis of drug response predicting biomarkers in PDXE dataset. For each tissue type and drug, association between genomic features (mutation copy number variation and gene expression) and drug response in PDXs are reported.
Supplementary Data File 6 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Arvind S. Mer,Wail Ba-Alawi,Petr Smirnov,Yi X. Wang,Ben Brew,Janosch Ortmann,Ming-Sound Tsao,David W. Cescon,Anna Goldenberg,Benjamin Haibe-Kains

DOI: https://doi.org/10.1158/0008-5472.22421111.v1

2023-01-01

Abstract:Association between drug class and pathways in PDXs. Drugs have been classified into categories according to their known target and association is computed using gene set enrichment analysis.
Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Mengyu Xie,Hong Zheng,Ranjna Madan-Lala,Wenjie Dai,Nicholas T. Gimbrone,Zhihua Chen,Fumi Kinose,Sarah A. Blackstone,Keiran S.M. Smalley,W. Douglas Cress,Eric B. Haura,Uwe Rix,Amer A. Beg

DOI: https://doi.org/10.1158/0008-5472.22422747

2023-01-01

Abstract:Drug screening data used in Figure 2 are shown, including drug names, cell viability and expression levels of chemokines.
Supplementary Figure from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or Without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Alberto A. Chiappori,Ben Creelan,Tawee Tanvetyanon,Jhanelle E. Gray,Eric B. Haura,Ram Thapa,Margaret L. Barlow,Zhihua Chen,Dung Tsa Chen,Amer A. Beg,Theresa A. Boyle,Julio Castro,Liza Morgan,Erick Morris,Mehreteab Aregay,Felipe K. Hurtado,Luigi Manenti,Scott Antonia

DOI: https://doi.org/10.1158/1078-0432.ccr-21-2742

IF: 13.801

2022-01-01

Clinical Cancer Research

Abstract:Supplementary Figure from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer
Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Jeff Hsu,Colin Chong,Jeffrey Serrill,Levina Goon,Joan Balayan,Eric N. Johnson,Grachelle Lorenzana,Sharon Wu,Kevin G. Leong,Theodore J. Yun,Yong Wang,Faming Jiang,Lynne Bannen,Peter Lamb,Wei Xu,Peiwen Yu

DOI: https://doi.org/10.1158/1535-7163.22523460

2023-01-01

Abstract:Supplementary Figures and Tables with adjoining Legends
Supplementary Data File S6 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Natalia Filippova,Xiuhua Yang,Subramaniam Ananthan,Jennifer Calano,Vibha Pathak,Larry Bratton,Rakesh H. Vekariya,Sixue Zhang,Edward Ofori,Emily N. Hayward,David Namkoong,David K. Crossman,Michael R. Crowley,Peter H. King,James A. Mobley,Louis B. Nabors

DOI: https://doi.org/10.1158/0008-5472.22429090.v1

2023-01-01

Abstract:File (tmp-LBN-Report_PH-DMPK-UAB-19-001_SRI-42127 _Mouse IP Plasma Brain PK) provides pharmacokinetic data for Fig. S14.
Comparison of the Circulating Metabolite Profile of PF-04991532, a Hepatoselective Glucokinase Activator, Across Preclinical Species and Humans: Potential Implications in Metabolites in Safety Testing Assessment

Raman Sharma,John Litchfield,Arthur Bergman,Karen Atkinson,David Kazierad,Stephanie M. Gustavson,Li Di,Jeffrey A. Pfefferkorn,Amit S. Kalgutkar

DOI: https://doi.org/10.1124/dmd.114.061218

2014-11-10

Drug Metabolism and Disposition

Abstract:A previous report from our laboratory disclosed the identification of PF-04991532 [(S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid] as a hepatoselective glucokinase activator for the treatment of type 2 diabetes mellitus. Lack of in vitro metabolic turnover in microsomes and hepatocytes from preclinical species and humans suggested that metabolism would be inconsequential as a clearance mechanism of PF-04991532 in vivo. Qualitative examination of human circulating metabolites using plasma samples from a 14-day multiple ascending dose clinical study, however, revealed a glucuronide (M1) and monohydroxylation products (M2a and M2b/M2c) whose abundances (based on UV integration) were greater than 10% of the total drug-related material. Based on this preliminary observation, mass balance/excretion studies were triggered in animals, which revealed that the majority of circulating radioactivity following the oral administration of [¹⁴C]PF-04991532 was attributed to an unchanged parent (>70% in rats and dogs). In contrast with the human circulatory metabolite profile, the monohydroxylated metabolites were not detected in circulation in either rats or dogs. Available mass spectral evidence suggested that M2a and M2b/M2c were diastereomers derived from cyclopentyl ring oxidation in PF-04991532. Because cyclopentyl ring hydroxylation on the C-2 and C-3 positions can generate eight possible diastereomers, it was possible that additional diastereomers may have also formed and would need to be resolved from the M2a and M2b/M2c peaks observed in the current chromatography conditions. In conclusion, the human metabolite scouting study in tandem with the animal mass balance study allowed early identification of PF-04991532 oxidative metabolites, which were not predicted by in vitro methods and may require additional scrutiny in the development phase of PF-04991532.

pharmacology & pharmacy
Supplementary Data File S2 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Natalia Filippova,Xiuhua Yang,Subramaniam Ananthan,Jennifer Calano,Vibha Pathak,Larry Bratton,Rakesh H. Vekariya,Sixue Zhang,Edward Ofori,Emily N. Hayward,David Namkoong,David K. Crossman,Michael R. Crowley,Peter H. King,James A. Mobley,Louis B. Nabors

DOI: https://doi.org/10.1158/0008-5472.22429105

2023-01-01

Abstract:File (tmp-LBN-Inhibitor vs DMSO DESeq2 annotated results with normalized counts) provides RNA-Seq annotated data for Fig. 6 and Table 1, which illustrate transcriptome analysis for PDGx neurospheres treated with SRI-42127 compound versus control.
Drug Metabolite Cluster-Based Data-Mining Method For Comprehensive Metabolism Study Of 5-Hydroxy-6,7,3 ',4 '-Tetramethoxyflavone In Rats

Yuqi Wang,Xiaodan Mei,Zihan Liu,Jie Li,Xiaoxin Zhang,Shuang Lang,Long Dai,Jiayu Zhang

DOI: https://doi.org/10.3390/molecules24183278

IF: 4.6

2019-01-01

Molecules

Abstract:The screening of drug metabolites in biological matrixes and structural characterization based on product ion spectra is among the most important, but also the most challenging due to the significant interferences from endogenous species. Traditionally, metabolite detection is accomplished primarily on the basis of predicted molecular masses or fragmentation patterns of prototype drug metabolites using ultra-high performance liquid chromatography coupled with high-resolution mass spectrometry (UHPLC-HRMS). Although classical techniques are well-suited for achieving the partial characterization of prototype drug metabolites, there is a pressing need for a strategy to enable comprehensive drug metabolism depiction. Therefore, we present drug metabolite clusters (DMCs), different from, but complementary to, traditional approaches for mining the information regarding drugs and their metabolites on the basis of raw, processed, or identified tandem mass spectrometry (MS/MS) data. In this paper, we describe a DMC-based data-mining method for the metabolite identification of 5-hydroxy-6,7,3 ',4 '-tetramethoxyflavone (HTF), a typical hydroxylated-polymethoxyflavonoid (OH-PMF), which addressed the challenge of creating a thorough metabolic profile. Consequently, eight primary metabolism clusters, sixteen secondary metabolism clusters, and five tertiary metabolism clusters were proposed and 106 metabolites (19 potential metabolites included) were detected and identified positively and tentatively. These metabolites were presumed to generate through oxidation (mono-oxidation, di-oxidation), methylation, demethylation, methoxylation, glucuronidation, sulfation, ring cleavage, and their composite reactions. In conclusion, our study expounded drug metabolites in rats and provided a reference for further research on therapeutic material basis and the mechanism of drugs.
Supplemental Data from HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy

Tongzheng Liu,Yuan Fang,Haoxing Zhang,Min Deng,Bowen Gao,Nifang Niu,Jia Yu,SeungBaek Lee,JungJin Kim,Bo Qin,Fang Xie,Debra Evans,Liewei Wang,Wenhui Lou,Zhenkun Lou

DOI: https://doi.org/10.1158/0008-5472.22409697.v1

2023-01-01

Abstract:Supplemental data includes supplement materials, methods and data
Stable Isotope- and Mass Spectrometry-Based Metabolomics As Tools in Drug Metabolism: A Study Expanding Tempol Pharmacology

Fei Li,Xiaoyan Pang,Kristopher W. Krausz,Changtao Jiang,Chi Chen,John A. Cook,Murali C. Krishna,James B. Mitchell,Frank J. Gonzalez,Andrew D. Patterson

DOI: https://doi.org/10.1021/pr301023x

2013-01-01

Journal of Proteome Research

Abstract:The application of mass spectrometry-based metabolomics in the field of drug metabolism has yielded important insights not only into the metabolic routes of drugs but has provided unbiased, global perspectives of the endogenous metabolome that can be useful for identifying biomarkers associated with mechanism of action, efficacy, and toxicity. In this report, a stable isotope- and mass spectrometry-based metabolomics approach that captures both drug metabolism and changes in the endogenous metabolome in a single experiment is described. Here the antioxidant drug tempol (4-hydroxy-2,2,6,6-tetramethylpiperidine-N-oxyl) was chosen because its mechanism of action is not completely understood and its metabolic fate has not been studied extensively. Furthermore, its small size (MW = 172.2) and chemical composition (C(9)H(18)NO(2)) make it challenging to distinguish from endogenous metabolites. In this study, mice were dosed with tempol or deuterated tempol (C(9)D(17)HNO(2)) and their urine was profiled using ultraperformance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Principal component analysis of the urinary metabolomics data generated a Y-shaped scatter plot containing drug metabolites (protonated and deuterated) that were clearly distinct from the endogenous metabolites. Ten tempol drug metabolites, including eight novel metabolites, were identified. Phase II metabolism was the major metabolic pathway of tempol in vivo, including glucuronidation and glucosidation. Urinary endogenous metabolites significantly elevated by tempol treatment included 2,8-dihydroxyquinoline (8.0-fold, P < 0.05) and 2,8-dihydroxyquinoline-β-d-glucuronide (6.8-fold, P < 0.05). Urinary endogenous metabolites significantly attenuated by tempol treatment including pantothenic acid (1.3-fold, P < 0.05) and isobutrylcarnitine (5.3-fold, P < 0.01). This study underscores the power of a stable isotope- and mass spectrometry-based metabolomics in expanding the view of drug pharmacology.
Supplementary Data DS1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Xuyang Song,Robin K. Kelley,Anis A. Khan,Nathan Standifer,Diansong Zhou,KyoungSoo Lim,Rajesh Krishna,Lu Liu,Kun Wang,Patricia McCoon,Alejandra Negro,Philip He,Megan Gibbs,John F. Kurland,Ghassan K. Abou‐Alfa

DOI: https://doi.org/10.1158/1078-0432.22490323.v1

2023-01-01

Abstract:Supplementary Data for publication
Supplementary Data from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Natalia Filippova,Xiuhua Yang,Subramaniam Ananthan,Jennifer Calano,Vibha Pathak,Larry Bratton,Rakesh H. Vekariya,Sixue Zhang,Edward Ofori,Emily N. Hayward,David Namkoong,David K. Crossman,Michael R. Crowley,Peter H. King,James A. Mobley,Louis B. Nabors

DOI: https://doi.org/10.1158/0008-5472.22429084.v1

2023-01-01

Abstract:Supplementary materials including tables, figures, and detailed methods.
Supplementary Data from <i>in Vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

Klaus P. Hoeflich,Carol O’Brien,Zachary Boyd,Guy Cavet,Steve Guerrero,Kenneth Jung,Tom Januario,Heidi Savage,Elizabeth A. Punnoose,Tom Truong,Wei Zhou,Leanne Berry,Lesley J. Murray,Lukas C. Amler,Marcia Belvin,Lori S. Friedman,Mark R. Lackner

DOI: https://doi.org/10.1158/1078-0432.22440072

2023-01-01

Abstract:Supplementary Data from In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
Characterization of the metabolites of H3B-6545 in vitro and in vivo by using ultra-high performance liquid chromatography combined with electrospray ionization linear ion trap-orbitrap tandem mass spectrometry

Dong Zhang,Xiuxian Hao,Lili Xu,Ying Yang,Hong Zhao

DOI: https://doi.org/10.1002/bmc.4746

Abstract:H3B-6545 is a selective ERα covalent antagonist, which has been demonstrated to be effective in anti-tumor. To fully understand its mechanism of action, it is necessary to investigate the in vitro and in vivo metabolic profiles. For in vitro metabolism, H3B-6545 (50 μM) was incubated with the hepatocytes of rat and human for 2 h. For in vivo metabolism H3B-6545 was orally administered to rats at a single dose of 10 mg/kg, and plasma, urine and fecal samples were then collected. All samples were analyzed by using ultra-high performance liquid chromatography combined with linear ion trap-orbitrap tandem mass spectrometry (UHPLC-LTQ-Orbitrap-MS) operated in positive ion mode. The structures of the metabolites were elucidated by comparing their MS and MS2 spectra with those of parent drug. A total of 11 metabolites, including a GSH adduct, were detected and structurally identified. M2, M7 and M8 were further unambiguously identified by using reference standards. Among these metabolites, M1, M5, M7 and M10 were newly found and reported for the first time. The metabolic pathways of H3B-6545 included deamination (M8 and M9), dealkylation (M2, M3 and M10), N-hydroxylation (M6), hydroxylation (M1 and M4), formation of amide derivatives (M5 and M7) and GSH conjugation (G1).
Abstract 2478: Development of a novel HIF2a PET tracer: From proof of concept to a clinical trial

Sashi Debnath,Christina Stevens,Olivia Brandenburg,Justin Sovich,Paulina Gonzalez,Qian (Janie) Qin,Sydney Haldeman,Vanina Toffessi Tcheuyap,Alana Christie,Pawan Thapa,Ning Zhou,Aditi Mulgaonkar,Guiyang Hao,Jeffrey Miyata,Deyssy Carrillo,Jeffrey Cadeddu,Payal Kapur,Jon Anderson,Ivan Pedrosa,Marianna Dakanali,Orhan Oz,Xiankai Sun,James Brugarolas

DOI: https://doi.org/10.1158/1538-7445.am2022-2478

IF: 11.2

2022-06-17

Cancer Research

Abstract:Normally induced by hypoxia, hypoxia-inducible factor 2 alpha (HIF2a) is arguably the most important driver of kidney cancer. HIF2a is constitutively activated following von Hippel-Lindau (VHL) gene inactivation, which is the signature event of the most common type of kidney cancer, clear cell renal cell carcinoma (ccRCC). HIF2a functions as a heterodimeric transcription factor in partnership with the constitutive HIF1b subunit and regulates a program of gene expression that promotes cell proliferation, stemness, and angiogenesis. While as a transcription factor HIF2a had escaped drug targeting, structural studies revealed an unusual cavity, which became the foundation for the development of small molecule inhibitors such as PT2385 (a first-in-class drug), or the related PT2399 tool compound and the recently FDA-approved PT2977 (also called belzutifan). PT drugs bind a small pocket in the PAS-B domain of HIF2a inducing a conformational change that triggers dissociation from its obligatory partner HIF1b. PT drugs are highly specific - they do not bind the close paralog HIF1a and do not induce changes in gene expression in cells devoid of HIF2a. Using an extensive library of patient-derived xenografts (PDXs), we previously showed that PT drugs have activity against 50% of ccRCCs implanted in mice, and similar observations were made in the clinic. Perhaps unsurprisingly, sensitive tumors showed higher HIF2a levels. Here, we leverage the specificity of PT2385 to develop a HIF2a tracer for positron emission tomography (PET). By substituting a native fluorine atom for 18F, we generated [18F]PT2385. [18F]PT2385 was able to discriminate HIF2a-expressing ccRCCs from tumors that did not express HIF2a in mice simultaneously implanted with both. These data set the foundation for an investigator new drug (IND) approval from the FDA, and a clinical trial that is currently accruing patients (NCT04989959). [18F]PT2385 PET may have applications in identifying kidney cancer patients most likely to respond to HIF2a-targeted therapies, the identification of other tumors relying on HIF2a, and beyond oncology. Reporting on a hypoxia sensor, a HIF2a radiotracer may be a useful ischemia probe. In summary, we report the development of a novel radiotracer with extensive potential applications currently being evaluated in humans. Citation Format: Sashi Debnath, Christina Stevens, Olivia Brandenburg, Justin Sovich, Paulina Gonzalez, Qian (Janie) Qin, Sydney Haldeman, Vanina Toffessi Tcheuyap, Alana Christie, Pawan Thapa, Ning Zhou, Aditi Mulgaonkar, Guiyang Hao, Jeffrey Miyata, Deyssy Carrillo, Jeffrey Cadeddu, Payal Kapur, Jon Anderson, Ivan Pedrosa, Marianna Dakanali, Orhan Oz, Xiankai Sun, James Brugarolas. Development of a novel HIF2a PET tracer: From proof of concept to a clinical trial [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl) nr 2478.

oncology
Supplementary Data File S1 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Natalia Filippova,Xiuhua Yang,Subramaniam Ananthan,Jennifer Calano,Vibha Pathak,Larry Bratton,Rakesh H. Vekariya,Sixue Zhang,Edward Ofori,Emily N. Hayward,David Namkoong,David K. Crossman,Michael R. Crowley,Peter H. King,James A. Mobley,Louis B. Nabors

DOI: https://doi.org/10.1158/0008-5472.22429108.v1

2023-01-01

Abstract:File (DATA FILE S1 Lead optimization-SAR-Chemical compound synthesis-11-03-2020-SZ v4, pdf format 297 pages) provides a detailed and sequential description of the chemical synthesis of compounds evaluated in this study and a docking study for SRI-42127 compound with SRI-42127-binding sites at HuR.

Supplemental Data for Metabolic profiling of the novel HIF 2 α inhibitor PT 2385 in vivo and in vitro in Drug Metabolism and Disposition

Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2α Inhibitor PT2385 In Vivo and In Vitro.

Supplementary Data File 3 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 4 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 5 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Data File 6 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

Supplementary Table 2 from MEK Inhibition Modulates Cytokine Response to Mediate Therapeutic Efficacy in Lung Cancer

Supplementary Figure from Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or Without Spartalizumab (PDR001), in Patients with Advanced Non–Small Cell Lung Cancer

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Data File S6 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Comparison of the Circulating Metabolite Profile of PF-04991532, a Hepatoselective Glucokinase Activator, Across Preclinical Species and Humans: Potential Implications in Metabolites in Safety Testing Assessment

Supplementary Data File S2 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Drug Metabolite Cluster-Based Data-Mining Method For Comprehensive Metabolism Study Of 5-Hydroxy-6,7,3 ',4 '-Tetramethoxyflavone In Rats

Supplemental Data from HEATR1 Negatively Regulates Akt to Help Sensitize Pancreatic Cancer Cells to Chemotherapy

Stable Isotope- and Mass Spectrometry-Based Metabolomics As Tools in Drug Metabolism: A Study Expanding Tempol Pharmacology

Supplementary Data DS1 from Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Supplementary Data from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Supplementary Data from &lt;i&gt;in Vivo&lt;/i&gt; Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models

Characterization of the metabolites of H3B-6545 in vitro and in vivo by using ultra-high performance liquid chromatography combined with electrospray ionization linear ion trap-orbitrap tandem mass spectrometry

Abstract 2478: Development of a novel HIF2a PET tracer: From proof of concept to a clinical trial

Supplementary Data File S1 from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Supplementary Data from <i>in Vivo</i> Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models